Benzinga | May 6, 2021 12:08PM EDT

Needham Maintains Buy on Autolus Therapeutics, Lowers Price Target to $21

Needham maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and lowers the price target from $26 to $21.